Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Response to BNT162b2 in Pediatric Kidney Transplant and Dialysis Patients
NCT05465863Completed
- Sponsor
- Istanbul University-Cerrahpaşa
- Start
- Sep 2021
- Primary completion
- Feb 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Open-label trial of tozinameran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Istanbul University-Cerrahpaşa. Primary endpoints: Anti-SARS-CoV-2 immunoglobulin G and Neutralizing antibody. Started Sep 2021; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05465863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05465863.